2024 SABCS Meeting Magazine - 12

SCHEDULE-AT-A-GLANCE
7:00 - 8:30 a.m.
Concurrent Poster Spotlight
Sessions
HEMISFAIR BALLROOM 1-2
* Poster Spotlight 2:
Personalizing CDK 4/6
Inhibitor Therapy for
Patients with Metastatic
Breast Cancer: Survival,
QOL, and Biomarkers
Moderator: Lisa Carey, UNC
Lineberger Comprehensive
Cancer Center, Chapel Hill,
North Carolina
ROOM 221 ABC
* Poster Spotlight 6:
Locoregional Therapy
Moderator: Mylin Torres,
Winship Cancer Institute of
Emory University, Atlanta,
Georgia
STARS AT NIGHT 1-2
* Poster Spotlight 8: Novel
HER2 Therapeutics
Moderator: Ian Krop, Yale
School of Medicine, New
Haven, Connecticut
STARS AT NIGHT 3-4
* Poster Spotlight 9: ctDNA
Uses for Minimal Residual
Disease Testing, Tumor
Evolution, and Novel
Technologies
Moderator: Charles
Perou, UNC Lineberger
Comprehensive Cancer
Center, Chapel Hill, North
Carolina
ROOM 221 ABC
* Poster Spotlight 15:
Survivorship: Biomarker
Predictors and Other
Survival-associated Factors
Moderator: Lindsay Peterson,
Washington University
Siteman Cancer Center, St.
Louis, Missouri
8:30 - 9:00 a.m.
Plenary Lecture
HALL 1
Moderator: Virginia Kaklamani, UT
Health Mays Cancer Center, San
Antonio, Texas
* The Grand Challenge of
Unraveling Social vs Biological
Drivers of Racial Disparities in
Cancer Outcomes
Melissa B. Davis, Morehouse
School of Medicine, Atlanta,
Georgia
12
9:00 - 11:45 a.m.
General Session 2
HALL 1
Moderators: Michael Gnant,
Medical University of Vienna,
Vienna, Austria, and Zhi-Ming Shao,
Fudan University Shanghai Cancer
Center, Shanghai, China
* GS2-01: Exclusive endocrine
therapy or radiation therapy
in women aged 70+ years
with luminal-like early
breast cancer (EUROPA):
preplanned interim analysis
of a randomized phase 3 trial.
Icro Meattini, University of
Florence, Florence, Italy
* GS2-02: Impact of
Tamoxifen Only after Breast
Conservation Surgery
for " Good Risk " Duct
Carcinoma in Situ: Results
from the NRG Oncology/
RTOG 9804 and ECOGACRIN
E5194 Trial
Jean Wright, University of North
Carolina School of Medicine,
Chapel Hill, North Carolina
* GS2-03: Does postmastectomy
radiotherapy in 'intermediate-risk'
breast cancer impact
overall survival? 10-year
results of the BIG 2-04 MRC
SUPREMO randomised trial:
on behalf of the SUPREMO
trial investigators.
Ian Kunkler, Edinburgh Cancer
Centre, University of Edinburgh,
Edinburgh, Scotland
* GS2-04: Discussant
Elinor Sawyer, King's College
London, London, United Kingdom
* GS2-05: Early Oncologic
Outcomes Following Active
Monitoring or Surgery (+/Radiation)
for Low Risk DCIS:
the Comparing an Operation
to Monitoring, with or without
Endocrine Therapy (COMET)
Study (AFT-25).
Eun-Sil Hwang, Duke
University School of Medicine,
Durham, North Carolina
* GS2-06: Patient Reported
Outcomes Following Active
Monitoring or Surgery (+/Radiation)
for Low Risk
DCIS in the Comparing an
Operation to Monitoring,
with or without Endocrine
Therapy (COMET) Study
(AFT-25).
Ann Partridge, Dana-Farber
Cancer Institute, Boston,
Massachusetts
* GS2-07: No axillary surgery
versus axillary sentinel
lymph node biopsy in
patients with early invasive
breast cancer and breastconserving
surgery:
Final primary results of
the Intergroup-SentinelMamma
(INSEMA) trial.
Toralf Reimer,
Universitätsmedizin Rostock,
Rostock, Germany
* GS2-08: Discussant
Puneet Singh, MD Anderson
Cancer Center, Houston, Texas
* GS2-09: Overweight,
obesity and prognosis in
206,904 women in the Early
Breast Cancer Trialists'
Collaborative Group
(EBCTCG) database.
Hongchao Pan, University of
Oxford, Oxford, United Kingdom
* GS2-10: A long-term
image-derived AI risk model
for primary prevention of
breast cancer.
Mikael Eriksson, Karolinska
Institutet, Solna, Sweden
* GS2-11: APOBEC3
mutagenesis induces
resistance-promoting
genomic alterations in
breast cancer.
Avantika Gupta, Memorial
Sloan Kettering Cancer
Center, New York, New York
12:00 - 12:50 p.m.
Rapid Fire 2
HALL 1
Moderator: Carlos Arteaga, UT
Southwestern Medical Center,
Dallas, Texas
* RF2-01: Factors Influencing
Additional Nodal Disease
and Pathologic Nodal
Upstaging with Axillary
Dissection in Patients with
Residual Node-Positive
Breast Cancer After
Neoadjuvant Chemotherapy
Enrolled on Alliance
A011202 Clinical Trial.
Judy Boughey, Mayo Clinic,
Rochester, Minnesota
* RF2-02: Axillary surgery
after neoadjuvant systemic
therapy (NST) for earlystage
breast cancer
- Treatment algorithms
and prognostic impact of
residual micrometastases in
five neoadjuvant studies.
Johannes Holtschmidt, VP
Medicine & Research GBG
Forschungs GmbH
* RF2-03: Diagnostic
performance of axillary
ultrasound after neoadjuvant
chemotherapy in initially
node-positive breast cancer
patients - results from the
prospective AXSANA registry
trial (NCT04373655).
Steffi Hartmann, University of
Rostock, Rostock, Germany
* RF2-04:
Ultrahypofractionated versus
conventional fractionated
sequential boost after wholebreast
radiation therapy
in breast cancer patients.
One-year cosmetic outcomes
of a randomized, controlled,
phase 3 trial (ULTIMO).
Melanie Machiels, Universiteit
Antwerpen, Antwerp, Belgium
* RF2-05: Validation of the
association between TILs,
ER status and benefit
of radiotherapy in node
positive, breast cancer
patients: a DBCG study.
Demet Özcan, Aarhus University
Hospital, Aarhus, Denmark
* RF2-06: A Nationwide
Double-Blind Phase III RCT
Comparing Olanzapine
and Prochlorperazine for
Refractory ChemotherapyInduced
Nausea in NCORP
Community Practices.
Luke Peppone, University of
Rochester Medical Center,
Rochester, New York
12:30 - 2:00 p.m.
Poster Session 3
HALLS 2-3
12:30 - 1:45 p.m.
Risk Reduction and Early
Detection: The Future of
Cancer Genetics Is Here
STARS AT NIGHT 3-4
Moderator: Claudine Isaacs,
Georgetown University,
Washington, DC
2024 SABCS®
| Meeting Magazine
2024 SABCS Meeting Magazine

Table of Contents for the Digital Edition of 2024 SABCS Meeting Magazine
